Rivaroxaban submitted for wider approval in EU

04/12/2012 | Fox Business

Bayer is seeking EU authorization to market anti-coagulant rivaroxaban as a pulmonary embolism therapy. Partner Johnson & Johnson will apply this quarter for FDA approval of rivaroxaban to treat venous thromboembolism, a Bayer spokeswoman said.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD